How can we avoid clinical stage failures and get drugs to patients faster? We share our thoughts on navigating R&D with evidence from large human populations in this latest Cell Trends in Biotechnology article.

‍

Reducing clinical failures is the biggest opportunity in drug development: 90% of drugs fail in clinical trials, with 50% failing for efficacy reasons.

‍

Stakeholders lack critical evidence on whether their drug target will work in humans before trialing for it, and they lack tools to use insights on target biology to optimize clinical positioning. Human evidence from large populations offers critical insights to navigate and de-risk R&D: ensure target safety and efficacy at the earliest stages and align target biology with the right clinical phenotypes benefitting from target modulation.

‍

Read the full article to learn more!

‍

‍